Abstract
Study design:
Using a complete transection spinal cord injury (SCI) model at the fourth thoracic vertebral level in adult rats, we evaluated whether blocking noxious stimuli below the injury diminishes abnormal somatic and autonomic motor reflexes, manifested in muscular spasticity and hypertensive autonomic dysreflexia, respectively. Gabapentin (GBP) is well tolerated and currently used to manage neuropathic pain in the SCI population; evidence suggests that it acts to decrease presynaptic glutamate release. As clinical evidence indicates that GBP may suppress muscular spasticity in the chronic SCI population, we hypothesized that preventing neurotransmission of noxious stimuli with GBP eliminates a critical physiological link to these distinct, debilitating SCI-induced secondary impairments.
Objectives:
Behavioural assessments of tail muscle spasticity and mean arterial blood pressure responses to noxious somatic and/or visceral stimulation were used to test the effects of GBP on these abnormal reflexes.
Setting:
Lexington, Kentucky.
Methods:
We used femoral artery catheterization and radio-telemetric approaches to monitor blood pressure alterations in response to noxious colorectal distension (CRD) weeks after complete SCI.
Results:
At 2–3 weeks post-SCI, acute GBP administration (50 mg kg−1, i.p.) significantly attenuated both autonomic dysreflexia and tail spasticity induced by noxious stimuli compared with saline-treated cohorts.
Conclusion:
These results show, for the first time, that a single-pharmacological intervention, GBP, can effectively attenuate the manifestation of both muscular spasticity and autonomic dysreflexia in response to noxious stimuli.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Kitzman P . Changes in vesicular glutamate transporter 2, vesicular GABA transporter and vesicular acetylcholine transporter labeling of sacrocaudal motoneurons in the spastic rat. Exp Neurol 2006; 197: 407–419.
Karlsson AK . Autonomic dysreflexia. Spinal Cord 1999; 37: 383–391.
Krassioukov AV, Furlan JC, Fehlings MG . Autonomic dysreflexia in acute spinal cord injury: an under-recognized clinical entity. J Neurotrauma 2003; 20: 707–716.
Kitzman PH, Uhl TL, Dwyer MK . Gabapentin suppresses spasticity in the spinal cord-injured rat. Neuroscience 2007; 149: 813–821.
Wheeler G . Gabapentin. Pfizer. Curr Opin Investig Drugs 2002; 3: 470–477.
Coderre TJ, Kumar N, Lefebvre CD, Yu JS . Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. J Neurochem 2005; 94: 1131–1139.
Shimoyama M, Shimoyama N, Hori Y . Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. Pain 2000; 85: 405–414.
Gruenthal M, Mueller M, Olson WL, Priebe MM, Sherwood AM, Olson WH . Gabapentin for the treatment of spasticity in patients with spinal cord injury. Spinal Cord 1997; 35: 686–689.
Priebe MM, Sherwood AM, Graves DE, Mueller M, Olson WH . Effectiveness of gabapentin in controlling spasticity: a quantitative study. Spinal Cord 1997; 35: 171–175.
Cameron AA, Smith GM, Randall DC, Brown DR, Rabchevsky AG . Genetic manipulation of intraspinal plasticity after spinal cord injury alters the severity of autonomic dysreflexia. J Neurosci 2006; 26: 2923–2932.
Stevenson VL . Rehabilitation in practice: spasticity management. Clin Rehabil 2010; 24: 293–304.
Montane E, Vallano A, Laporte JR . Oral antispastic drugs in nonprogressive neurologic diseases: a systematic review. Neurology 2004; 63: 1357–1363.
Anderson KD . Targeting recovery: priorities of the spinal cord injured population. J Neurotrauma 2004; 21: 1371–1383.
Krassioukov AV, Weaver LC . Episodic hypertension due to autonomic dysreflexia in acute and chronic spinal cord-injured rats. Am J Physiol 1995; 268 (5 Part 2): H2077–H2083.
Maiorov DN, Weaver LC, Krassioukov AV . Relationship between sympathetic activity and arterial pressure in conscious spinal rats. Am J Physiol 1997; 272 (2 Pt 2): H625–H631.
Maiorov DN, Krenz NR, Krassioukov AV, Weaver LC . Role of spinal NMDA and AMPA receptors in episodic hypertension in conscious spinal rats. Am J Physiol 1997; 273 (3 Pt 2): H1266–H1274.
Mayer NH . Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Muscle Nerve Suppl 1997; 6: S1–S13.
Walter JS, Sacks J, Othman R, Rankin AZ, Nemchausky B, Chintam R et al. A database of self-reported secondary medical problems among VA spinal cord injury patients: its role in clinical care and management. J Rehabil Res Dev 2002; 39: 53–61.
Mayorov DN, Adams MA, Krassioukov AV . Telemetric blood pressure monitoring in conscious rats before and after compression injury of spinal cord. J Neurotrauma 2001; 18: 727–736.
Rabchevsky AG, Duale H, Lyttle TS, O’Dell CR, Kitzman PH . Gabapentin for spasticity and autonomic dysreflexia after severe spinal cord injury. J Neurotrauma 2009; 26: A1–A65.
Acknowledgements
This study was supported by NIH/NINDS R01 NS049901 and Kentucky Spinal Cord and Head Injury Research Trust (KSCHIRT) 3–11 (AGR), KSCHIRT 4–8 (PHK) and NIH/NINDS P30 NS051220.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Rabchevsky, A., Patel, S., Duale, H. et al. Gabapentin for spasticity and autonomic dysreflexia after severe spinal cord injury. Spinal Cord 49, 99–105 (2011). https://doi.org/10.1038/sc.2010.67
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sc.2010.67
Keywords
This article is cited by
-
Effect of GR205171 on autonomic dysreflexia induced by colorectal distension in spinal cord injured rats
Spinal Cord (2023)
-
Autonomic dysreflexia associated with cervical spinal cord gliofibroma: case report
BMC Neurology (2021)
-
Flumazenil therapy for a gabapentin-induced coma: a case report
Journal of Medical Case Reports (2021)
-
Preclinical models of muscle spasticity: valuable tools in the development of novel treatment for neurological diseases and conditions
Naunyn-Schmiedeberg's Archives of Pharmacology (2016)
